« News

TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Helsinn Healthcare SA

Helsinn, the Swiss Group focused on building quality cancer care, and Australian biopharmaceutical company Specialised Therapeutics Australia (STA), announce that the Therapeutic Goods Administration (TGA) has approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy1.

2015-05-08- Akynzeo approved in Australia.pdf